Insight Molecular Diagnostics Inc. Common Stock
Follow $IMDX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $IMDX by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is IMDX moving today?
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
IMDX overview
Related filings and maps
Congress activity in IMDX
No receipt-qualified filings found.
IMDX contract awards, year to date.
Public federal awards linked to this ticker.
IMDX lobbying filings, year to date.
Registered lobbying filings matched to Insight Molecular Diagnostics Inc. Common Stock.